



Profile of Tobacco Use in Patients with Schizophrenia

Thesis

Submitted for Partial Fulfillment of M.D Degree in

Psychiatry

By

Lobna AbuBakr Ismail Azzam

M.B., B.Ch, M. Sc.- Ain Shams University

Supervised by

Prof. Nahla Alsayed Nagi

Professor of Psychiatry

Faculty of Medicine - Ain Shams University

Prof. Ghada Refaat Amin

Professor of Psychiatry

Faculty of Medicine - Ain Shams University

Assis. Prof. Mahmoud Mamdouh El-Habiby

Assistant Professor of Psychiatry

Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

2017

Abstract

Background: Although much attention has been drawn to trends in smoking and smoking related diseases in the general population, increasing evidence suggests that individuals suffering from mental illness are at increased risk for tobacco use and nicotine addiction. Smoking is the single greatest preventable cause of death in our society. It is recently demonstrated that, in smokers compared with nonsmokers with schizophrenia, the risk of mortality is doubled, and the risk of cardiac-related mortality is increased about 12-fold.

Aims: To study the pattern of tobacco use among schizophrenic patients. To measure how schizophrenic perceive the effect and risk of tobacco use in relation to their symptoms. To study the degree of motivation to quit in patients with schizophrenia. To highlight factors that increase severity in tobacco use in schizophrenia.

Methodology: Study design: A case control study. Site of the study: The outpatient clinic and inpatient in the institute of psychiatry of Ain Shams University. Ain Shams University is located in Eastern Cairo and serves a catchment area of about the third of Greater Cairo. It serves both urban and rural areas, including areas around Greater Cairo as well.

Results: The sample was consisting of patients with the diagnosis of schizophrenia attending the outpatient clinic or inpatient of the institute of psychiatry Ain Shams University Hospitals. The sample size were consisted of 180 patients and they were selected randomly.

Conclusion: This is study emphasize on the relation between tobacco smoking and schizophrenia, it demonstrate the pattern of smoking in the given sample of patients with schizophrenia who underwent treatment in inpatient and outpatient facilities.

Recommendation: Test the Nicotine dependence as a part of the routine assessment of patients with schizophrenia. Further research of tobacco smoking in patients with schizophrenia a larger multi-center study to involve patients with different sociodemographic variables

Keywords: Tobacco, Smoking, Schizophrenia

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



ACKNOWLEDGEMENT

*First, I thank **Allah** for granting me the power to proceed and to accomplish this work,*

*I would like to express my deepest gratitude and ultimate thanks to **Prof. Nahla Alsayed Nagi** Professor of Psychiatry, Faculty of medicine, Ain Shams University, for her scientific guidance, and for her trust in my performance and my work.*

*I am eternally grateful to **Prof. Ghada Refaat** Amin, Professor of Psychiatry, Ain Shams University for her great help and kind advice. She gave me much of her time, effort and her great experience and knowledge.*

*I assert my thanks to **Dr. Mahmoud Mamdouh El-Habiby**, Assistant Professor of Psychiatry, Faculty of Medicine, Ain Shams University, for his faithful guidance, valuable comments and constructive criticism, meticulous revision, helping me to accomplish this work, the best it could be.*

I would like to extend my thanks to all my professors, colleagues and friends, so many of them influenced, encouraged and inspired me throughout the years.

I also want to thank my patients for their extreme cooperation and even prayers.

Finally, I would like to express my love and respect to my family for their valuable emotional support and continuous encouragement which brought the best out of me.

Dedication

Dedicated to the one who inspired me

Throughout my whole life to the

Soul of My Father



Contents

Subjects	Page
List of abbreviations.....	II
List of figures.....	IV
List of tables.....	V
• Introduction	1
• Rationale of the work	8
• Review of Literature	
♦ Chapter (1): Epidemiology	11
♦ Chapter (2): Direction of Causality	22
♦ Chapter (3): Management	51
• Subjects and Methods	79
• Results	89
• Discussion	123
• Summary	149
• Conclusion	163
• Recommendation	164
• Limitations and Strengths	166
• References	167
• Arabic Summary	

List of Abbreviations

AMPA	: Alpha amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
BDNF	: Brain derived neurotrophic factors
CO	: Carbon monoxide
COMT	: Catechol-Omethyltransferase
CYP	: Cytochrome P
DA	: Dopamine
DBH	: Dopamine beta hydroxylase
DNA	: Deoxyribonucleic acid
EEG	: Electroencephalography
EMG	: Electromyographic
EPA	: European psychiatric association
ERP	: Event -related potentials
Fmri	: Functional magnetic resonance imaging
FTND	: Fagerstrom Test for Nicotine Dependence
GABA	: Gamma-Aminobutyric acid
GAD	: Glutamic acid decarboxylase
GLU	: Glutamate
5HT	: 5 hydroxytryptamine

List of Abbreviations

Kg	: Kilogram
LWDS- 11	: Lebanon Waterpipe Dependence Scale-11
MMN	: Mismatch negativity
MOA	: Monoamine oxidase
mRNA	: Messenger ribonucleic acid
nAChRs	: Nicotinic acetylcholine receptors
NMDA	: <i>N</i> -methyl-d-aspartate
NRT	: Nicotine replacement therapy
PANSS	: Positive and negative syndrome scale
PPI	: Prepulse inhibition
RFQ	: Reason for quitting scale
SCID	: Structured clinical Interview for DSM
SCQ-A	: Smoking consequences questionnaire –Adult
SNPs	: Single nucleotide polymorphisms
SPEM	: Smooth pursuit eye movement
VTa	: Ventral tegmental area
WISDM-68	: Wisconsin inventory of smoking dependence motives

List of Figures

<u>No.</u>	<u>Figure</u>	<u>Page</u>
<u>1</u>	Advertisement for Philips Morris	15
<u>2</u>	Prevalence rate of tobacco use in psychiatric illnesses	17
<u>3</u>	Use of specific tobacco products in mentally ill versus non mentally ill people	19

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>1</u>	Prevalence of smoking in general population versus mentally ill people.	19
<u>2</u>	Prevalence of tobacco use in different psychiatric illnesses.	20
<u>3</u>	Factors related to smoking in mentally ill people.	21
<u>4</u>	Summary of factors of correlation between smoking and schizophrenia.	49
<u>5</u>	Difference between patients with schizophrenia and non schizophrenic subjects as regard smoking cessation.	74
<u>6</u>	Comparison between cases and controls regarding age of smoking, FTND and LWDS.	89
<u>7</u>	Correlations between age, age of smoking, FTND score, LWDS and PANSS.	90
<u>8</u>	Correlation between symptoms and morning smoking preference.	91
<u>9</u>	Correlation between symptoms of schizophrenia (PANSS) AND the number of cigarettes, time spent before first cigarette and number of stones.	93
<u>10</u>	Correlation between symptoms of schizophrenia (PANSS) and shisha smoking.	96
<u>11</u>	Correlation between symptoms (PANSS) and social facilitation effect of shisha.	98

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>12</u>	Correlation between symptoms (PANSS) and mood elevation effect of shisha.	100
<u>13</u>	Correlation between symptoms (PANSS) and seeking pleasure from shisha smoking.	102
<u>14</u>	Correlation between symptoms (PANSS) and lowering anxiety effect of shisha.	104
<u>15</u>	Comparison between cases and controls regarding SCQ.	106
<u>16</u>	Comparison between cases and controls regarding WISDM-68.	108
<u>17</u>	Comparison between cases and controls regarding LWDS (Motives of shisha smoking).	110
<u>18</u>	Correlations between PANSS and SCQ	111
<u>19</u>	Regression analysis of the Correlations between Positive scale score and SCQ.	113
<u>20</u>	Correlations between PANSS and WISDM-68.	114
<u>21</u>	Regression analysis of the Correlations between positive scale score and WISDM-68.	116
<u>22</u>	Comparison between cases and controls regarding socio-demographic data.	117
<u>23</u>	Description of age, duration, course and type of schizophrenia.	118
<u>24</u>	Comparison between cases and controls regarding RFQ scale.	119

List of Tables

<u>No.</u>	<u>Table</u>	<u>Page</u>
<u>25</u>	Correlations between PANSS and RFQ scale.	120
<u>26</u>	Regression analysis of the Correlations between Positive scale score and RFQ scale.	122

Introduction

Although much attention has been drawn to trends in smoking and smoking related diseases in the general population, increasing evidence suggests that individuals suffering from mental illness are at increased risk for tobacco use and nicotine addiction (*Lasser et al., 2000*).

Smoking is the single greatest preventable cause of death in our society. It is recently demonstrated that, in smokers compared with nonsmokers with schizophrenia, the risk of mortality is doubled, and the risk of cardiac-related morality is increased about 12-fold (*Kelly et al., 2011*).

People with schizophrenia have a high prevalence of smoking with reported rates of 58%–90% (*Moeller, 2008*). This is considerably higher than smoking rates of 24% (*NSDUH, 2009*) in the general public and approximately 50% in people with other psychiatric diagnoses (*Baker et al., 2006*).

Additionally, people with schizophrenia who smoke are also heavier smokers than smokers in the general population. Although the causes of this high prevalence are not known, increased smoking in schizophrenia is believed to be due to a complex interaction of psychological,

behavioral, and environmental factors (*Kelly & McCreddie, 1999*).

It was believed in the past that heavy and frequent cigarette smoking in people with schizophrenia was attributable to boredom, institutionalization, or cigarette rewards for good behavior on treatment units (*Hughes et al., 1986*).

More recently, it has been recognized that smoking represents more than “something to do.” Cigarette smoking may partially represent an attempt at self-medication to control symptoms not addressed by antipsychotic medications (*Simosky et al., 2002*).

Studies of the effects of nicotine in people with schizophrenia have shown improvements in areas including learning and memory, eye tracking, prepulse inhibition of acoustic startle response, and P50 sensory inhibition (*Barr et al., 2008*). Additionally, smoking is associated with reduced akathisia (*Barnes et al., 2006*).

There is evidence implicating the nicotinic cholinergic system, specifically the $\alpha 7$ nicotinic receptor, in the pathophysiology of schizophrenia (*Martin & Freedman, 2007*). Activation of the nicotinic acetylcholine receptors can increase glutamate release onto layer V pyramidal neurons of the prefrontal cortex. This is

important because schizophrenia pathology also involves abnormal cortical activation, n-methyl-D-aspartate (NMDA) hypofunction, and difficulty with cognition (*Lambe et al., 2003*).

NMDA hypofunction may contribute to cognitive impairments associated with schizophrenia, and agents targeting both nicotinic and NMDA receptors may show promise for improving cognitive deficits present in many people with this illness (*Kantrowitz & Javitt, 2010*).

The self-medication hypothesis has been increasingly used to explain the high association between smoking and schizophrenia, the mechanisms include possible regulation of central dopamine availability by pharmacodynamic and pharmacokinetic processes (e.g. enzyme induction of the hepatic enzyme system, lowering antipsychotic effectiveness). These processes have also been implicated in reducing the side-effects of dopamine blockade of typical antipsychotics. More recently, based on a number of preclinical and clinical studies, this theory proposes that patients with schizophrenia smoke in order to ‘treat’ underlying negative symptoms and cognitive deficits (*Matthews et al., 2011*).